Breaking News Instant updates and real-time market news.

ATRS

Antares Pharma

$3.79

0.54 (16.62%)

13:57
10/02/18
10/02
13:57
10/02/18
13:57

Jefferies raises Antares Pharma price target to $7, sees possible upside to $15

Jefferies analyst Anthony Petrone raised his price target on Antares Pharma to $7 from $5, calling FDA approval of Xyosted a "game changer." He does not believe the inclusion of a black box warning in the label is a significant surprise nor a deal breaker for doctors, Petrone tells investors. The analyst, who thinks the company could take anywhere from 20% to 60% of the $1.5B-$2.0B TRT market over time, sees upside to $15 on a strong roll out of Xyosted, he added. Petrone keeps a Buy rating on Antares shares, which are up 17.5% to $3.83 in afternoon trading.

  • 02

    Oct

ATRS Antares Pharma
$3.79

0.54 (16.62%)

10/23/17
RAJA
10/23/17
NO CHANGE
Target $3.4
RAJA
Strong Buy
Antares Pharma maintained as a Strong Buy at Raymond James
Raymond James analyst Elliot Wilbur said the FDA's CRL on Antares Pharma (ATRS) XYOSTED was an unexpected and significant setback, but weakness in shares since the October disclosure effectively prices XYOSTED at zero, and substantially undervalues other development programs, especially ANDA products with Teva (TEVA). Wilbur is not writing-off XYSTED yet and is pushing out an expected launch to 2H19 from early 2018 previously, and is now discounting the probability of success at 50% versus 100% prior to the CRL. The analyst maintains asset values for Antares' non-XYOSTED assets are worth $2.50 per share using a sum-of-the-parts valuation and adjusted his price target to $3.40 from $4.20 on shares. Wilbur maintains a Strong Buy rating on Antares
10/23/17
JANY
10/23/17
NO CHANGE
JANY
Neutral
Antares CRL doesn't raise issues for Amag Pharmaceuticals, says Janney Capital
Janney Capital analyst Ken Trbovich noted that the FDA complete response letter issued to Antares (ATRS) for Xyosted did not pertain to the Quickshot subcutaneous autoinjector, which raises his confidence the FDA will not identify such issues as a short coming of the sNDA for Amag Pharmaceuticals' (AMAG) Makena SQ. However, he keeps a Neutral rating on Amag shares, noting that the primary uncertainty for the sNDA for Makena SQ is the fact that its peak plasma levels is higher than the upper bound the FDA uses to define bioequivalence.
05/08/18
HCWC
05/08/18
NO CHANGE
Target $4
HCWC
Buy
Antares target raised to $4 on higher Xyosted confidence at H.C. Wainwright
H.C. Wainwright analyst Oren Livnat said that Antares Pharma reported "solid" Q1 results but "most importantly...finally explicitly confirmed a key aspect of the Xyosted filing," specifically that the company already conducted an ambulatory blood pressure monitoring study as part of the supplemental safety study ahead of the NDA submission. That fact, along with Antares' ability to re-submit the NDA just a week after receiving the minutes from the FDA Type-A meeting, increases his confidence in Xyosted approval coming in 2018, Livnat said. He raised his view of Xyosted's probability of success to 70% from 40% and increased his price target to $4 from $3.50 on Antares shares. Livnat keeps a Buy rating on the stock.
08/17/18
HCWC
08/17/18
NO CHANGE
Target $4.5
HCWC
Buy
H.C. Wainwright ups Antares price target to $4.50 after generic EpiPen approval
After the FDA announced the "long-awaited" approval of Antares Pharma (ATRS) and partner Teva's (TEVA) generic EpiPen, H.C. Wainwright analyst Oren Livnat said his estimates include nearly $40M in peak EpiPen revenue to Antares from the "biggest partnered pipeline opportunity" the company has modeled by his and consensus estimates. Livnat, who said he is not aware of any other substitutable EpiPen generics on the way, views the product as a sustainable contributor and raised his price target on Antares shares to $4.50 from $4.00 following the news. Livnat, who assumes Teva launches quickly after final label packaging, but believes that Teva "unfortunately" will miss the big EpiPen back-to-school prescribing season, keeps a Buy rating on Antares shares.

TODAY'S FREE FLY STORIES

11:25
01/16/19
01/16
11:25
01/16/19
11:25
Conference/Events
UBS communications/media analysts to hold a luncheon meeting »

Communications &…

BLK

BlackRock

$416.74

16.51 (4.13%)

11:23
01/16/19
01/16
11:23
01/16/19
11:23
Hot Stocks
BlackRock says Fink letter 'coming soon' after fake version circulated »

BlackRock's official…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 23

    Jan

  • 29

    Jan

  • 11

    Feb

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
01/16/19
01/16
11:17
01/16/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
01/16/19
01/16
11:16
01/16/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CF

CF Industries

$42.03

-1.26 (-2.91%)

11:15
01/16/19
01/16
11:15
01/16/19
11:15
Options
CF Industries put volume heavy and directionally bearish »

Bearish flow noted in CF…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

11:15
01/16/19
01/16
11:15
01/16/19
11:15
General news
U.S. VIX equity volatility rose 1.8% to probe 19.0 »

U.S. VIX equity…

SIG

Signet Jewelers

$33.76

-0.05 (-0.15%)

11:14
01/16/19
01/16
11:14
01/16/19
11:14
Hot Stocks
Signet Jewelers says to pay total of $11M to CFPB, NYS in investigations »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWLO

Twilio

$98.39

-2.03 (-2.02%)

11:13
01/16/19
01/16
11:13
01/16/19
11:13
Rumors
Rumor moving shares of Twilio »

Rumor: Twilio moves off…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 12

    Feb

11:10
01/16/19
01/16
11:10
01/16/19
11:10
General news
Treasury Action: curve steepening has been the general trend this year »

Treasury Action: curve…

SQ

Square

$66.03

0.13 (0.20%)

, FISV

Fiserv

$70.17

-4.84 (-6.45%)

11:09
01/16/19
01/16
11:09
01/16/19
11:09
Recommendations
Square, Fiserv, First Data analyst commentary  »

Fiserv deal for First…

SQ

Square

$66.03

0.13 (0.20%)

FISV

Fiserv

$70.17

-4.84 (-6.45%)

FDC

First Data

$20.72

3.17 (18.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 03

    Mar

11:05
01/16/19
01/16
11:05
01/16/19
11:05
General news
FX Action: USD-JPY »

FX Action: USD-JPY topped…

YELP

Yelp

$35.64

0.67 (1.92%)

11:03
01/16/19
01/16
11:03
01/16/19
11:03
Hot Stocks
Breaking Hot Stocks news story on Yelp »

Yelp says to review…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YELP

Yelp

$35.65

0.68 (1.94%)

11:03
01/16/19
01/16
11:03
01/16/19
11:03
Hot Stocks
Breaking Hot Stocks news story on Yelp »

Yelp says 'willing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YELP

Yelp

$35.65

0.68 (1.94%)

11:03
01/16/19
01/16
11:03
01/16/19
11:03
Hot Stocks
Yelp says 'open to hearing ideas and investor input, including from SQN' »

Yelp issued the following…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JWN

Nordstrom

$43.85

-3.41 (-7.22%)

11:02
01/16/19
01/16
11:02
01/16/19
11:02
Downgrade
Nordstrom rating change  »

Nordstrom downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

KEYS

Keysight Technologies

$68.05

-0.47 (-0.69%)

11:01
01/16/19
01/16
11:01
01/16/19
11:01
Hot Stocks
Keysight Technologies, others sign agreement with UNISOC »

Keysight Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDSI

BioDelivery Sciences

$4.24

0.08 (1.92%)

11:00
01/16/19
01/16
11:00
01/16/19
11:00
Options
Call buyer in BioDelivery Sciences International as the rally continues »

Call buyer in BioDelivery…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:00
01/16/19
01/16
11:00
01/16/19
11:00
General news
Energy Action: NYMEX crude »

Energy Action: NYMEX…

JPM

JPMorgan

$102.15

0.45 (0.44%)

10:55
01/16/19
01/16
10:55
01/16/19
10:55
Conference/Events
Economic Club of New York to hold a luncheon meeting »

JPMorgan Chairman &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 26

    Feb

APA

Apache

$31.93

0.17 (0.54%)

10:50
01/16/19
01/16
10:50
01/16/19
10:50
Options
Aggressive option play opened in Apache as shares extend gains »

Aggressive option play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Feb

EA

Electronic Arts

$86.34

-3.14 (-3.51%)

, ATVI

Activision Blizzard

$45.89

-0.92 (-1.97%)

10:48
01/16/19
01/16
10:48
01/16/19
10:48
Recommendations
Electronic Arts, Activision Blizzard analyst commentary  »

Stephens a buyer of…

EA

Electronic Arts

$86.34

-3.14 (-3.51%)

ATVI

Activision Blizzard

$45.89

-0.92 (-1.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

  • 12

    Feb

  • 25

    Feb

UAL

United Continental

$86.50

5.27 (6.49%)

10:48
01/16/19
01/16
10:48
01/16/19
10:48
Hot Stocks
United Continental 'paying close attention to government shutdown' »

CEO Oscar Munoz says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 04

    Mar

DB

Deutsche Bank

$9.01

0.39 (4.52%)

10:42
01/16/19
01/16
10:42
01/16/19
10:42
Periodicals
Deutsche Bank regulators said to favor European merger, Bloomberg says »

The ECB is said to favor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,088.98

12.07 (1.12%)

, GOOGL

Alphabet Class A

$1,098.50

12.14 (1.12%)

10:42
01/16/19
01/16
10:42
01/16/19
10:42
Hot Stocks
Google's YouTube banning 'dangerous challenges and pranks' »

In an update to their…

GOOG

Alphabet

$1,088.98

12.07 (1.12%)

GOOGL

Alphabet Class A

$1,098.50

12.14 (1.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 04

    Feb

  • 04

    Feb

  • 25

    Feb

  • 03

    Mar

SM

SM Energy

$20.07

0.24 (1.21%)

10:40
01/16/19
01/16
10:40
01/16/19
10:40
Options
Bullish option flow in SM Energy after analyst action »

Bullish option flow in SM…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.